特发性膜性肾病治疗中的争议
Controversies in the treatment of idiopathic membranous nephropathy.
作者信息
Waldman Meryl, Austin Howard A
机构信息
Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Nat Rev Nephrol. 2009 Aug;5(8):469-79. doi: 10.1038/nrneph.2009.101. Epub 2009 Jul 7.
Abstract
Optimum treatment of idiopathic membranous nephropathy is both controversial and challenging. The most extensively studied and frequently used immunosuppressive regimens for this disease comprise alkylating agents plus corticosteroids or ciclosporin. All of these treatment options have inherent problems: they are not effective in all patients, partial-rather than complete-remissions are common, adverse effects are worrisome, and relapses after treatment cessation remain problematic. Alternative immunosuppressive agents have been tested in an effort to overcome these unresolved issues. This paper reviews the available evidence regarding both established and new agents for the treatment of patients with idiopathic membranous nephropathy, with an emphasis on the results of the most recent clinical trials.
摘要
特发性膜性肾病的最佳治疗方案既存在争议，又具有挑战性。针对该疾病，研究最广泛且使用最频繁的免疫抑制方案包括烷化剂加皮质类固醇或环孢素。所有这些治疗方案都存在固有问题：它们并非对所有患者都有效，部分缓解而非完全缓解很常见，不良反应令人担忧，且停药后复发问题依然存在。人们已对其他免疫抑制剂进行了试验，试图克服这些尚未解决的问题。本文回顾了有关治疗特发性膜性肾病的既有药物和新药物的现有证据，重点是最新临床试验的结果。
相似文献
1
Controversies in the treatment of idiopathic membranous nephropathy.特发性膜性肾病治疗中的争议
Nat Rev Nephrol. 2009 Aug;5(8):469-79. doi: 10.1038/nrneph.2009.101. Epub 2009 Jul 7.
2
Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs.皮质类固醇和环孢素A治疗特发性膜性肾病：与使用细胞毒性药物的传统治疗相比，肾病综合征缓解率更高，不良反应更少。
Am J Nephrol. 2007;27(3):226-31. doi: 10.1159/000101367. Epub 2007 Mar 27.
3
Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征特发性膜性肾病的免疫抑制治疗
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD004293. doi: 10.1002/14651858.CD004293.pub3.
4
Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.合成促肾上腺皮质激素用于特发性膜性肾病高危患者：一项前瞻性、开放标签队列研究。
PLoS One. 2015 Nov 12;10(11):e0142033. doi: 10.1371/journal.pone.0142033. eCollection 2015.
5
Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.特发性膜性肾病老年患者的临床病理特征及预后。
Ren Fail. 2023 Dec;45(1):2212081. doi: 10.1080/0886022X.2023.2212081.
6
The remission of nephrotic syndrome with cyclosporin treatment does not attenuate the progression of idiopathic membranous nephropathy.环孢素治疗肾病综合征的缓解并不能减缓特发性膜性肾病的进展。
Clin Nephrol. 2004 Jan;61(1):17-24. doi: 10.5414/cnp61017.
7
Renal outcomes of idiopathic and atypical membranous nephropathy in adult Chinese patients: a single center retrospective cohort study.成年中国患者特发性和非典型膜性肾病的肾脏转归：一项单中心回顾性队列研究
BMC Nephrol. 2021 Apr 22;22(1):148. doi: 10.1186/s12882-021-02348-4.
8
Immunosuppressive treatment for nephrotic idiopathic membranous nephropathy: a meta-analysis based on Chinese adults.免疫抑制治疗特发性膜性肾病：基于中国成年人的荟萃分析。
PLoS One. 2012;7(9):e44330. doi: 10.1371/journal.pone.0044330. Epub 2012 Sep 5.
9
Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.他克莫司联合皮质类固醇与改良庞蒂切利方案治疗特发性膜性肾病的随机对照试验
Nephrology (Carlton). 2016 Feb;21(2):139-46. doi: 10.1111/nep.12569.
10
Predictors of response and relapse in patients with idiopathic membranous nephropathy treated with tacrolimus.他克莫司治疗特发性膜性肾病患者的反应和复发的预测因素。
Nephrol Dial Transplant. 2015 Mar;30(3):467-74. doi: 10.1093/ndt/gfu306. Epub 2014 Oct 1.
引用本文的文献
1
Clinical evaluation of strengthening spleen and draining dampness in the treatment of idiopathic membranous nephropathy: a retrospective 10-year follow-up study.健脾利湿法治疗特发性膜性肾病的临床评价：一项10年回顾性随访研究
J Tradit Chin Med. 2025 Aug;45(4):881-890. doi: 10.19852/j.cnki.jtcm.2025.04.018.
2
Impact of immune cell metabolism on membranous nephropathy and prospective therapy.免疫细胞代谢对膜性肾病的影响及前瞻性治疗
Commun Biol. 2025 Mar 10;8(1):405. doi: 10.1038/s42003-025-07816-3.
3
Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.成人肾病综合征中原发性膜性肾病的免疫抑制治疗。
Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
4
Tetrandrine may treat membranous glomerulopathy via P13K/Akt signaling pathway regulation: therapeutic mechanism validation using Heymann nephritis rat model.汉防己甲素可能通过调控 P13K/Akt 信号通路治疗膜性肾小球病：以 Heymann 肾炎大鼠模型为对象的治疗机制验证。
Bioengineered. 2021 Dec;12(1):6499-6515. doi: 10.1080/21655979.2021.1973862.
5
A Point-of-Care Immunosensor Based on a Quartz Crystal Microbalance with Graphene Biointerface for Antibody Assay.基于具有石墨烯生物界面的石英晶体微天平的即时检测免疫传感器用于抗体检测。
ACS Sens. 2020 Nov 25;5(11):3520-3532. doi: 10.1021/acssensors.0c01641. Epub 2020 Oct 25.
6
A nomogram for the prediction of renal outcomes among patients with idiopathic membranous nephropathy.用于预测特发性膜性肾病患者肾脏预后的列线图。
Exp Ther Med. 2020 Oct;20(4):3130-3137. doi: 10.3892/etm.2020.9063. Epub 2020 Jul 28.
7
Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.利妥昔单抗治疗膜性肾病的疗效与安全性：一项系统评价和荟萃分析。
Medicine (Baltimore). 2020 Apr;99(16):e19804. doi: 10.1097/MD.0000000000019804.
8
Clinical observation and analysis of thyroid hormone levels in patients with idiopathic membranous nephropathy.特发性膜性肾病患者甲状腺激素水平的临床观察与分析
Medicine (Baltimore). 2020 Feb;99(7):e19106. doi: 10.1097/MD.0000000000019106.
9
A novel Time-resolved Fluoroimmunoassay for the quantitative detection of Antibodies against the Phospholipase A2 Receptor.一种新型时间分辨荧光免疫分析法，用于定量检测抗磷脂酶 A2 受体抗体。
Sci Rep. 2017 Apr 11;7:46096. doi: 10.1038/srep46096.
10
Treatment pattern in patients with idiopathic membranous nephropathy-practices in Sweden at the start of the millennium.千禧年初瑞典特发性膜性肾病患者的治疗模式与实践。
Clin Kidney J. 2016 Apr;9(2):227-33. doi: 10.1093/ckj/sfv152. Epub 2016 Jan 27.
本文引用的文献
1
Current therapies for lupus nephritis in an ethnically heterogeneous cohort.种族异质性队列中狼疮性肾炎的当前治疗方法。
J Rheumatol. 2009 Feb;36(2):298-305. doi: 10.3899/jrheum.080335.
2
Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.利妥昔单抗对膜性肾小球病形态功能异常的影响。
Clin J Am Soc Nephrol. 2008 Nov;3(6):1652-9. doi: 10.2215/CJN.01730408. Epub 2008 Aug 6.
3
4
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.霉酚酸酯单药治疗膜性肾病：一项为期1年的随机对照试验。
Am J Kidney Dis. 2008 Oct;52(4):699-705. doi: 10.1053/j.ajkd.2008.04.013. Epub 2008 Jun 30.
5
What have we learned from the use of ciclosporin A in the treatment of nephrotic patients with idiopathic membranous nephropathy?我们从使用环孢素A治疗特发性膜性肾病的肾病患者中学到了什么？
Expert Opin Pharmacother. 2008 Jul;9(10):1695-704. doi: 10.1517/14656566.9.10.1695.
6
Role of remission clinics in the longitudinal treatment of CKD.缓解诊所在慢性肾脏病纵向治疗中的作用。
J Am Soc Nephrol. 2008 Jun;19(6):1213-24. doi: 10.1681/ASN.2007090970. Epub 2008 Mar 19.
7
Primary glomerulonephritis: an update on renal survival and determinants of progression.原发性肾小球肾炎：肾脏存活率及疾病进展决定因素的最新进展
QJM. 2008 Mar;101(3):215-24. doi: 10.1093/qjmed/hcm142. Epub 2008 Feb 2.
8
Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome.霉酚酸酯与泼尼松龙治疗膜性肾病伴肾病综合征的前瞻性对照研究
Nephrology (Carlton). 2007 Dec;12(6):576-81. doi: 10.1111/j.1440-1797.2007.00822.x.
9
Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study.霉酚酸酯或标准疗法治疗膜性肾病和局灶节段性肾小球硬化症：一项初步研究。
Nephrol Dial Transplant. 2008 Jun;23(6):1926-30. doi: 10.1093/ndt/gfm538. Epub 2007 Nov 7.
10
Rituximab treatment of idiopathic membranous nephropathy.利妥昔单抗治疗特发性膜性肾病。
Kidney Int. 2008 Jan;73(1):117-25. doi: 10.1038/sj.ki.5002628. Epub 2007 Oct 17.
Zotero 插件